AstraZeneca PLC (NASDAQ:AZN) Receives $89.75 Average Price Target from Brokerages

Shares of AstraZeneca PLC (NASDAQ:AZN) have received a consensus rating of “Buy” from the nine analysts that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $89.75.

AZN has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th.

Institutional Trading of AstraZeneca

Institutional investors and hedge funds have recently made changes to their positions in the company. McClarren Financial Advisors Inc. grew its position in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares in the last quarter. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca in the third quarter valued at approximately $28,000. Albion Financial Group UT increased its position in shares of AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after acquiring an additional 248 shares during the last quarter. Groupama Asset Managment lifted its holdings in AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after acquiring an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC bought a new position in AstraZeneca in the 3rd quarter valued at $45,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.6 %

AstraZeneca stock opened at $68.60 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $212.73 billion, a PE ratio of 32.82, a PEG ratio of 1.13 and a beta of 0.46. The firm’s fifty day moving average is $66.26 and its 200 day moving average is $74.28. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. The business’s revenue was up 18.0% on a year-over-year basis. As a group, sell-side analysts predict that AstraZeneca will post 4.12 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.